/KLDO
KLDO Stock - Kaleido Biosciences, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KLDO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.17
52W High$0.19
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $1.10M | $975,000 | N/A | N/A | N/A |
| Gross Profit | $-1,254,000 | $-54,992,000 | $-1,318,000 | N/A | N/A |
| Gross Margin | -113.6% | -5640.2% | N/A | N/A | N/A |
| Operating Income | $-87,667,000 | $-78,874,000 | $-86,660,000 | $-60,683,000 | $-27,030,000 |
| Net Income | $-90,288,000 | $-81,620,000 | $-85,013,000 | $-61,744,000 | $-27,559,000 |
| Net Margin | -8178.3% | -8371.3% | N/A | N/A | N/A |
| EPS | $-2.16 | $-2.44 | $-3.31 | $-2.10 | $-1.23 |
Company Overview
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
KLDOBeat Rate
33%
Last 12 quarters
Avg Surprise
-19.4%
EPS vs Estimate
Beats / Misses
4/5
3 met exactly
Latest EPS
$-0.47
Q2 2022
EPS Surprise History
Q3 20
0.0%
$-0.59vs$-0.59
Q4 20
-3.2%
$-0.65vs$-0.63
Q1 21
-40.0%
$-0.56vs$-0.40
Q2 21
+1.7%
$-0.58vs$-0.59
Q3 21
+1.8%
$-0.56vs$-0.57
Q4 21
0.0%
$-0.54vs$-0.54
Q4 21
No data
Q2 22
+19.0%
$-0.47vs$-0.58
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 22, 2023 | — | — | — | — |
Q1 2023 | Mar 27, 2023 | $-0.51 | — | — | — |
Q4 2022 | Dec 19, 2022 | — | — | — | — |
Q2 2022 | Apr 1, 2022 | $-0.58 | $-0.47 | +19.0% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q4 2021 | Nov 1, 2021 | $-0.54 | $-0.54 | 0.0% | = MET |
Q3 2021 | Aug 11, 2021 | $-0.57 | $-0.56 | +1.8% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.59 | $-0.58 | +1.7% | ✓ BEAT |
Q1 2021 | Mar 3, 2021 | $-0.40 | $-0.56 | -40.0% | ✗ MISS |
Q4 2020 | Nov 2, 2020 | $-0.63 | $-0.65 | -3.2% | ✗ MISS |
Q3 2020 | Aug 4, 2020 | $-0.59 | $-0.59 | 0.0% | = MET |
Q2 2020 | May 14, 2020 | $-0.64 | $-0.64 | 0.0% | = MET |
Q1 2020 | Mar 2, 2020 | $-0.34 | $-0.61 | -79.4% | ✗ MISS |
Q4 2019 | Oct 30, 2019 | $-0.89 | $-0.74 | +16.9% | ✓ BEAT |
Q3 2019 | Aug 1, 2019 | $-0.71 | $-0.83 | -16.9% | ✗ MISS |
Q2 2019 | May 2, 2019 | $-0.67 | $-1.56 | -132.8% | ✗ MISS |
Q1 2019 | Mar 1, 2019 | — | $-0.72 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.78 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.55 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.48 | — | — |
Latest News
Loading news...
Frequently Asked Questions about KLDO
What is KLDO's current stock price?
Kaleido Biosciences, Inc. (KLDO) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for KLDO?
No analyst price targets are currently available for this stock.
What sector is Kaleido Biosciences, Inc. in?
Kaleido Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is KLDO's market cap?
Kaleido Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does KLDO pay dividends?
No, Kaleido Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARNI
Arno Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BTTX
Better Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
BXRXQ
Baudax Bio, Inc.
$0.00
Mkt Cap: $0.0B
CALA
Calithera Biosciences, Inc.
$0.00
Mkt Cap: $0.0B
IVBT
Innovation1 Biotech Inc.
$0.00
Mkt Cap: $0.0B
SNNAQ
Sienna Biopharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
TLOG
TetraLogic Pharmaceuticals Corporation
$0.00
Mkt Cap: $0.0B
TNGNQ
Tengion, Inc.
$0.00
Mkt Cap: $0.0B
VIVE
Viveve Medical, Inc.
$0.00
Mkt Cap: $0.0B
XENO
Xeno Transplants Corporation
$0.00
Mkt Cap: $0.0B
Explore stocks similar to KLDO for comparison